197 related articles for article (PubMed ID: 24372206)
1. Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?
García AM; Redondo M; Martinez A; Gil C
Curr Med Chem; 2014 Apr; 21(10):1171-87. PubMed ID: 24372206
[TBL] [Abstract][Full Text] [Related]
2. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Schülke JP; Brandon NJ
Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.
García AM; Salado IG; Perez DI; Brea J; Morales-García JA; González-García A; Cadavid MI; Loza MI; Luque FJ; Perez-Castillo A; Martinez A; Gil C
Future Med Chem; 2017 May; 9(8):731-748. PubMed ID: 28485668
[TBL] [Abstract][Full Text] [Related]
4. Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.
Schülke JP; McAllister LA; Geoghegan KF; Parikh V; Chappie TA; Verhoest PR; Schmidt CJ; Johnson DS; Brandon NJ
ACS Chem Biol; 2014 Dec; 9(12):2823-32. PubMed ID: 25295858
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
[TBL] [Abstract][Full Text] [Related]
6. Emerging biology of PDE10A.
Wilson LS; Brandon NJ
Curr Pharm Des; 2015; 21(3):378-88. PubMed ID: 25159072
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
9. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
[TBL] [Abstract][Full Text] [Related]
10. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
Kehler J; Nielsen J
Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
12. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
13. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
14. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
[TBL] [Abstract][Full Text] [Related]
15. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
16. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
[TBL] [Abstract][Full Text] [Related]
17. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
Amin HS; Parikh PK; Ghate MD
Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Padovan-Neto FE; West AR
Adv Neurobiol; 2017; 17():257-283. PubMed ID: 28956336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
